5Nov, 2021
0
ECNP 2021 | Dual orexin receptor antagonists – the story so far and daridorexant Phase III data
For many years, GABAergic agents were the only pharmacological treatments available for patients with insomnia. Benzodiazepines and benzodiazepine receptor agonists are often used to treat insomnia, demonstrating short-term benefits on sleep onset latency and duration. However, pharmacological tolerance and cognitive side effects, amongst other associated harms, prevent their use long term. More recently, dual orexin (also known as hypocretin) receptor antagonists (DORAs) have emerged as a new treatment approach for patients with insomnia. Diego Garcia-Borreguero, MD, PhD, Sleep Research Institute, Madrid, Spain, discusses the role of orexin in sleep physiology […]
SABER MÁS
